Literature DB >> 9562010

Hypertrophic cardiomyopathy: role of the implantable cardioverter-defibrillator.

J Primo1, P Geelen, J Brugada, A L Filho, L Mont, F Wellens, M Valentino, P Brugada.   

Abstract

OBJECTIVES: We report the occurrence of cardiac events during long-term follow-up in patients with hypertrophic cardiomyopathy (HCM) after cardioverter-defibrillator implantation.
BACKGROUND: The identification of patients at high risk for sudden death and the prevention of recurrence of sudden death in HCM represents a difficult problem.
METHODS: We retrospectively analyzed the occurrence of cardiac events during follow-up of 13 patients with HCM who received an implantable cardioverter-defibrillator (ICD) because of aborted sudden death (n = 10) or sustained ventricular tachycardia (n = 3) (group I). Findings were compared with those in 215 patients with an ICD and other structural heart disease or idiopathic ventricular fibrillation (group II).
RESULTS: After a mean (+/-SD) follow-up period of 26+/-18 months, 2 of 13 patients in group I received appropriate shocks. The calculated cumulative incidence of shocks was 21% in group I and 66% in group II after 40 months (p < 0.05). We observed a low incidence of recurrence of ventricular tachycardia/fibrillation during follow-up in patients with HCM. No deaths occurred.
CONCLUSIONS: Our data suggest that ventricular tachyarrhythmias may not always be the primary mechanism of syncope and sudden death in patients with HCM. The ICD seems to have a less important impact on prognosis in patients with HCM than in patients with other etiologies of aborted sudden death.

Entities:  

Mesh:

Year:  1998        PMID: 9562010     DOI: 10.1016/s0735-1097(98)00037-0

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  4 in total

Review 1.  Implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: an updated systematic review and meta-analysis of outcomes and complications.

Authors:  Nelson Wang; Ashleigh Xie; Richard Tjahjono; David H Tian; Steven Phan; Tristan D Yan; Pietro Bajona; Kevin Phan
Journal:  Ann Cardiothorac Surg       Date:  2017-07

Review 2.  Hypertrophic cardiomyopathy: management issues in the new millennium.

Authors:  Rajesh Thaman; Sami Firoozi; M S Hamid; William J McKenna
Journal:  Curr Cardiol Rep       Date:  2002-05       Impact factor: 2.931

Review 3.  The role of pharmacologic treatment to prevent sudden death in the implantable cardioverter defibrillator era.

Authors:  P M Elliott
Journal:  Curr Cardiol Rep       Date:  2001-03       Impact factor: 2.931

Review 4.  Implantable cardioverter-defibrillator in hypertrophic cardiomyopathy.

Authors:  Diego Jimenez Sanchez; Ignacio Fernández Lozano
Journal:  Glob Cardiol Sci Pract       Date:  2018-08-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.